Prediction of the efficacy of intravesical BCG therapy in patients with bladder cancer based on the level of vascular endothelial growth factor, tumor necrosis factor α and β

Authors

  • V.S. Fedevych Danylo Halytsky Lviv National Medical University, Ukraine

DOI:

https://doi.org/10.26641/2307-5279.23.3.2019.178771

Keywords:

bladder cancer, vascular endothelial growth factor, tumor necrosis factor, polymorphism, intravesical BCG therapy

Abstract

In our study, we studied the effectiveness of the use of biomarker levels of vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-a and TNF-b in the urine of patients with bladder cancer (BC) to predict the effectiveness of intravesical BCG therapy at its early stage. The study included 35 adult patients with BC exclusively of the T1N0M0 stage, who underwent transurethral resection, the average age of which was 58.3±6.1 years. The mean values of the VEGF in the urine of patients with various degrees of neoplasia (G1, G2, G3) in the main group and in the comparison group did not have statistically significant differences between themselves before treatment and 6 weeks after (p>0.05). Thus, the determination of the levels of VEGF in urine did not demonstrate the appropriateness of their use in predicting the effectiveness of intravesical adjuvant BCG therapy in patients with BC stage T1N0M0. An increase in TNF-a in adjuvant intravesical BCG therapy in patients with BC stage T1N0M0 is associated with a positive therapeutic effect, which in our study was expressed in the absence of signs of disease recurrence. At the same time, the absence of an increase in this molecular marker 6 weeks after the initiation of BCG-inducing therapy indicated an insufficient inflammatory response (or its absence) and, as a consequence, a relapsing course of the disease. Like previously studied markers, the mean values of TNF-b in the urine of patients with various degrees of neoplasia (G1, G2, G3) in the main group and in the comparison group did not have statistically significant differences between themselves before treatment and 6 weeks after him (p> 0.05). The average level of the promoter of the inflammatory response of TNF-b increased at the 6th week after BCG instillation was closely associated with the positive therapeutic effect of inducing BCG therapy in patients with stage T1N0M0 RMP. Thus, the determination of molecular markers of VEGF, TNF-a and TNF-b in the urine of patients with bladder cancer after administration of intravesical BCG therapy can serve as the basis for the development of new methods of treatment and evaluation of their effectiveness.

References

Рак в Україні, 2017–2018. Захворюваність, смертність, показники діяльності онкологічної служби. Бюлетень Національного канцер-реєстру України № 20. Київ, 2019. С. 58–59.

Попков В.М., Понукалин А.Н., Захарова Н.Б. Фактор роста эндотелия сосудов в диагностике метастазов мышечно-инвазивного рака мочевого пузыря. Онкоурология. 2016. Т. 12, № 2. С. 53–57.

Fu D., Li P., Cheng W. et al. Impact of vascular endothelial growth factor gene-gene and gene-smoking interaction and haplotype combination on bladder cancer risk in Chinese population. Oncotarget. 2017. Vol. 8, No 14. P. 22927–22935.

Song Y., Yang Y., Liu L., Liu X. Association between five polymorphisms in vascular endothelial growth factor gene and urinary bladder cancer risk: A systematic review and meta-analysis involving 6671 subjects. Gene. 2019. Vol. 698. P. 186–197.

Wang J., Shen C., Fu Y., Yu T., Song J. The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis. Onco Targets Ther. 2017. Vol. 10. P. 1725–1734. DOI: 10.2147/OTT.S125965.

Stingl Jankovic K., Hudolin T., Kastelan Z., Zunec R., Grubic Z. The possible role of the tumour necrosis factor polymorphisms and human leucocyte antigens in the development of prostate cancer. Int J Immunogenet. 2016. Vol. 43, No 3. P. 143–150. DOI: 10.1111/iji.12262.

Song Y., Hu J., Chen Q. et al. Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): A meta-analysis involving 11,204 subjects. Gene. 2018. Vol. 679. P. 241–252.

Shen M., Zhou L., Zhou P., et al. Lymphotoxin b receptor activation promotes mRNA expression of RelA and pro-inflammatory cytokines TNFa and IL-1b in bladder cancer cells. Mol Med Rep. 2017. Vol. 16, No 1. P. 937–942. DOI: 10.3892/mmr.2017.6676.

Глантс С. Медико-биологическая статистика: пер. с англ. M.: Практика, 1998. 459 с.

Published

2019-09-21

Issue

Section

Oncourology